{"id":"NCT00527514","sponsor":"Daiichi Sankyo","briefTitle":"Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension","officialTitle":"A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2007-09-11","resultsPosted":"2009-09-23","lastUpdate":"2009-11-11"},"enrollment":185,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Amlodipine","otherNames":[]},{"type":"DRUG","name":"Olmesartan medoxomil plus amlodipine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.","primaryOutcome":{"measure":"Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring","timeFrame":"Baseline to 12 Weeks","effectByArm":[{"arm":"Overall Active Treatment Period","deltaMin":-21.4,"sd":0.8}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":185},"commonTop":["Nasopharyngitis","Oedema Peripheral","Upper respiratory tract infection","Dizziness","Joint swelling"]}}